Showing 3121-3130 of 5689 results for "".
- Zeiss Offers New SLT Application for the Visulas Green Therapeutic Laserhttps://modernod.com/news/zeiss-offers-new-slt-application-for-the-visulas-green-therapeutic-laser/2480842/Zeiss Medical Technology announced that it now offers the new SLT add-on to its Visulas green laser, part of an integrated glaucoma workflow designed to advance safe and effective glaucoma treatment. The new SLT laser feature offers unique protocols that may im
- CooperVision Seeks Proposals for 2022 Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-2022-science-and-technology-awards/2480832/To promote continuous advancement in contact lens research and development, CooperVision is now accepting submissions for its 2022 Science and Technology Awards program. The longstanding program fosters partnerships between recipients and CooperVision scientists to explore new dimensions in visio
- Opthea Presenting Clinical Data at ARVO 2022 Annual Meetinghttps://modernod.com/news/opthea-presenting-clinical-data-at-arvo-2022-annual-meeting/2480820/Opthea announced the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, Colorado from May 1-4, 2022 and virtually from May 11-12, 2022. Jason Slakter, MD, of
- Mireca Signs Deal with Graybug Vision to Develop Treatments for Inherited Retinal Diseaseshttps://modernod.com/news/mireca-signs-deal-with-graybug-vision-to-develop-treatments-for-inherited-retinal-diseases/2480755/
- Researchers Identify How Multiple Genes Impact Vision Development and Result in Rare Sight Disorderhttps://modernod.com/news/researchers-identify-how-multiple-genes-impact-vision-development-and-result-in-rare-sight-disorder/2480744/
- Heru Featured in Scientific Program with Hands-On Demonstrations at the 2022 Vision Expo East Annual Meetinghttps://modernod.com/news/heru-featured-in-scientific-program-with-hands-on-demonstrations-at-the-2022-vision-expo-east-annual-meeting/2480739/Heru, a provider of vision diagnostics, announced that the company will be featuring two new testing moda
- Penn Researchers Develop Gene Therapy that Restores Dim-Light Vision in Dogshttps://modernod.com/news/penn-researchers-develop-gene-therapy-that-restores-dim-light-vision-in-dogs/2480723/In the journal Proceedings of the National Academy of Sciences, University of Pennsylvania researchers reported a major advance: a gene therapy that returns night vision to dogs born with congenital stationary night blindness
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-us-lightsite-iii-clinical-trial-meets-primary-efficacy-endpoint-in-improving-vision-in-dry-amd-patients/2480712/LumiThera announced positive findings in its LIGHTSITE III multicenter clinical trial in non-neovascular (dry) age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked, randomized, multicenter clinica
- Study Shows Eyenovia's Optejet Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutionshttps://modernod.com/news/study-shows-eyenovias-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions/2480698/Eyenovia announced positive results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from latanoprost+benzalkonium chloride (BAK) treatment administered via